Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin specific peptidase 17 like family member 29 (USP17L29) is a member of the deubiquitinating enzyme family, functioning as a cysteine-type peptidase that removes ubiquitin moieties from specific proteins, thereby regulating multiple cellular processes such as cell proliferation, cell cycle progression, apoptosis, and cell migration. USP17L29 is rapidly induced in response to cytokine and chemokine stimulation and is necessary for both directional and random cell motility, acting downstream of chemokine receptors to facilitate cytoskeletal rearrangement via small GTPases. Its role in cell migration, proliferation, and survival implicates USP17L29 as a potential therapeutic target in inflammation, immune regulation, and cancer, particularly in processes related to metastasis and tissue invasion. No clinically approved drugs specifically target USP17L29, and inhibition may disrupt essential biological functions in both normal and malignant cells.
Inhibition of protein deubiquitination (hypothetical for investigational agents targeting DUB activity); Suppression of cell migration and proliferation if deubiquitinase activity is blocked
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin specific peptidase 17 like family member 29 (USP17L29).